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Summary: A new commercially available Chemiluminescence immunoassay for the quantitative measurement
of human chorionic gonadotropin and its -subunit in serum was compared with the enzyme immunoassay
used in our routine laboratory.
Human chorionic gonadotropin was determined in serum from pregnant women, as well as from women with
abortus inaminens, suspected ectopic pregnancies or with molar pregnancies.
The new human chorionic gonadotropin assay was also evaluated in combination with an automatic sample
processor for distributing samples to the antibody-coated wells of the microtitre plates.
The analytical precision, specificity and accuracy of the human chorionic gonadotropin assay were assessed
with 152 sera, using the 60 min^incubation as well as the shorter 15 min version. Specificity was comparable
with the conventional system, whereas the Chemiluminescence assay performed better with respect to the assay
detection limit and measuring range.
The enhanced Chemiluminescence system for the determination of human chorionic gonadotropin is an
efficient assay which agrees well with our routine assay. In connection with an automatic sample processor it
enables an advanced and versatile system for the determination of human chorionic gonadotropin in labo-
ratories with large series. The system is rapid, easy to handle and apparently free from interference.
Introduction _ 1 - 1 1 1 . * r ι· · ι ι_The gynaecological laboratory of our clinical chem-
Human chorionic gonadotropin, a glycoprotein com- istry department averages 10 — 20 serum samples per
posed of two dissimilar siibtinits (a and β), is mainly day for the quantitative measurement of human cho-
produced by normal and neoplastic trophpblasts (1). rionic gonadotropin. This high diagnostic require-
There is no known binding protein. In addition to the ment resulted in the replacement of formerly used
entire human chorionic gonadotropin molecule the radioimmunoassay for human chorionic gonadotro-
existence of free a- and -subunits has been demon- pin by similar techniques using non-isotopic labels in
strated (1 -r* 3). The determination of human chorionic our unit.
gonadotropih in serum is of great importance in the
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. . . . . * , - , Recently, the development of chemilummscence im-
momtonngof pregnancies, and in the assessment and , , .*[ . .~
-. * . ι t_ · -
 Λ munoassays has led to significant improvements, somanagement of gestational chonocarcmomas and a ,. . ,,
 4 . ,. , .. r .
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 A . f „ ,~ f^ τ t_ that these systems are suitable alternatives for thevariety of testicular germ cell tumours (2—5). It has ,, .
 /0 nx
u Λ **t Ι.· 'Λ ' r Λ j j other immunoassays (8,9).been proven that the combined use of ultrasound and
serial human chorionic gonadotropin determinations The coupling of horseradish peroxidase to the antigen
gives reliable information for the diagnosis of ectopic or to the antibody in place of the luminescent sub-
pregnancy, a cause of acute gynaecologic emergency strate together with the use of monoclonal antibodies
in premenopausal women (6,7). increased sensitivity and specificity in the quantitative
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determination of antigens in biological fluids (10).
Furthermore an enhanced luminescence technology
by addition of certain aromatic compounds to the
signal reagent made this assay format more conve-
nient (11, 12).
The Amerlite® system for the measurement of human
chorionic gonadotropin in serum represents an en-
hanced chemiluminescent immunoassay. First pre-
sented in 1986 the assay was carried out with mono-
clonal anitbodies in coated wells with two incubation
periods (first 2 h, then l h incubation time) (13). Now
an advanced version has been launched with a single
l h incubation step.
This article describes the evaluation of this new chemi-
luminescence assay format with regard to perform-
ance criteria; the system is compared with the Enzy-
mun-Test® immunoassay. In combination with the
semi-automatic ES-22 processor, the enzyme immu-
noassay for human chorionic gonadotropin is a com-
plete, proven and practical non-radioactive immu-
noassay system. Therefore we also checked the pos-
sibilities of connecting the Amerlite® system with an
automatic sample processor. With specially adapted
software programs, the liquid handling processor pre-
pares the way for the integration of this chemilumi-
nescence assay system on-line in our laboratory com-
puter system.
and washing unit, photometer, interface and assay-calculator
(Epson HX-20 with the program ELISA-22). The enzyme im-
munoassay for the determination of human chorionic gonad-
otropin and its -subunit in serum comprises two antibodies to
human chorionic gonadotropin. One monoclonal antibody is
coated to the tubes in which the assay is performed, the second
polyclonal one is labeled with peroxidase enzyme. The anti^
bodies form a sandwich complex with hutrfan chorionic gonado^
tropin -epitopes, the chromogenic substrate for visualizisation
of the bound complex is ABTS® (+ H2O2). The measuring
range is from 0 to 600 IU/1 human chorionic gonadotropin (1st
I. R. P. 72/537), sample volume 200 μΐ, incubation times 3 χ 30
min at 25 °C.
The Amerlite® system (Amersham International pic., Bucks,
U. K.) consists of a pipettes-workstation, an incubator, a wash
station and a luminescence analyser with integrated calculator
(software version 4.0). The microtitre wells of the human cho-
rionic gonadotropin-60 assay are coated with a polyclonal sheep
antibody to human chorionic gonadotropin, whereas the con-
jugate reagent contains a monoclonal mouse anti-human cho-
rionic gonadotropin labeled with peroxidase enzyme. The signal
reagent consists of lumhiol as substrate plus enhancer solution.
The measuring range is from 0 to 1000 IU/1 human chorionic
gonadotropin (1st I.R.P. 75/537), sample volume 50 μΐ, and
the incubation time 1 χ 60 min at 37 °C. A short version of
the assay format was performed with 1x15 min only.
Reagent and sample distributions for the Chemiluminescence
assay were performed manually or by using the TECAN fully
automatic sample processor RSP 5402 (Zinsser Analytic
GmbH, Frankfurt a. M., F. R. G.) with special software pro-
grams (on IBM PS/2) adapted to the human chorionic gonado-
tropin assay. All liquid handlings from prime rack to microtitre
plates were done by the processor with two robotic arms work-
ing independently from each other.
Materials and Methods
Patients and serum specimens
Blood samples (n = 152) were collected during two months
from more than 100 patients treated for threatened or ectopic
pregnancies, for abortus imminens, molar pregnancies or cho-
riocarcinomas, and from women, who were being monitored
for in-vitro fertilization. After clotting and centrifugation, the
sera were stored at 4 °C until determination of human chorionic
gonadotropin in both the immunoassays. Determinations with
the enzyme immunoassay showed a proportionate distribution
of human chorionic gonadotropin values randomly throughout
the concentration range. Pooled sera for the precision studies
of the Chemiluminescence assay were collected from more than
200 pregnant women and stored in 2 ml aliquots at —70 °C.
Three external control sera (Lyphocheck^ immunoassay control
sera) were used for the precision studies of the enzyme immu-
noassay (Bio-Rad Laboratories GmbH, M nchen, F. R. G.).
The measurements on the assay detection limit and the recovery
studies were performed using the first International Reference
Preparation of human chorionic gonadotropin (1st I.R.P. 75/
537).
Assay and ins t rumenta t ion characteristics
The Enzymun-Test® assay system ES-22 (Boehringer Mann-
heim, Mannheim, F. R. G.) is a modular batch analyser system
for semi-automatic performance of tests including a pipetting
Evaluation procedure
The Chemiluminescence assay and the enzyme immunoassay
were evaluated according to the recommendations given by
Singer et al. (14). The same competent laboratory staff was
involved during the entire trial. After an appropriate familiar-
ization period, all determinations were done in duplicate. The
Amerlite® human chorionic gonadotropin-60 kits had the batch
number LAN. 0083, lot CH-B:2. We compared the luminescence
and enzyme immunoassays with 152 consecutive sera. The short
version of the Chemiluminescence assay was compared with the
60 min version using 62 sera.
To ascertain the analytical detection limit of the Chemilumi-
nescence assay we calculated the detection limit as the human
chorionic gonadotropin value corresponding to the mean plus
3 χ standard deviation of the zero light intensity, measured 5
times in duplicate in separate assays.
To check the specificity of the two-site enhanced Chemilumi-
nescence assay we used 5 separate sera with high hypophyseal
gonadotropin contents. To check non-specific interferences we
analysed several haemolysed and lipaemic sera as well as 4 sera
with known monoclonal hyperimmunoglobulinaemia. Linearity
of sample dilutions, an essential attribute of perfected human
chorionic gonadotropin kits, was tested by diluting 2 high
human chorionic gonadotropiii sera consecutively; the meas-
ured light intensities were compared with the corresponding
ones of the standard samples series. The recovery, another
assessment of assay inaccuracy, was determined by measuring
the human chorionic gonadotropin concentrations following
the addition of known amounts of 1st I:R.P. standard to 2
sera with low human chorionic gonadotfopin contents.
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Results
Performance characteristics of the enhanced
chemiluminescence immunoassay for human
chorionic gonadotropin
Calibration
The two-site chemiluminescence assay produces a
standard curve up to a human chorionic gonadotropin
concentration of 1000 IU/1 in the typical shape of the
immunometric test principle. The analyser uses a non-
linear least squares regression technique to fit curves
and prints out a light index, which indicates whether
the light intensities obtained fall within the expected
range. Between 2 and 20 minutes after adding signal
reagent only minor dependences on the time of meas-
uring the standard curve can be seen (about 1 —2%
differences for the highest light intensities of the stand-
ards).
The chemiluminescence test kit contains 6 standards
based on serum, 3 kit control sera and 1 special high
sample diluent (see under "Detection limit").
Precision
Over the entire measuring range all mean coefficients
of variation (CV) clearly show a good precision of
Tab. 1. Reproducibility data for within- and between-series pre-
cision for the chemiluminescence and the enzyme im-
munoassay
Chemiluminescence assay
Within-series
precision
x (IU/1)
CV (%)
N
Between-series
precision
x (IU/1)
CV (%)
N
kit control 1
12.7
4.5
10
pool serum 1
30.5
6.7
10
kit control 2
271
2.7
10
pool serum 2
183
4.1
10
pool serum
745
1.5
10
pool serum 3
43950
4.0
10
Enzyme immunoassay
Within-series
precision
x (IU/1)
CV (%)
N
Between-series
precision
χ (iu/1)
CV (%)
N
control
serum 1
15.4
5.4
10
control
serum 1
62.5
8.1
31
control
serum 3
92.0
4.1
10
pool serum 1
190
3.5
31
pool serum
158
2.7
5
pool serum 2
382
4.7
31
the chemiluminescence assay with values between 1.5
and 4.5% in the intra-assay protocol and between 4.0
and 6.7% in the inter-assay study (see tab. 1). These
results are comparable with the CV's of the enzyme
immunoassay used in routine, which are also shown
in table 1.
The short 15 min version has a lower precision, but
the between-series precision is still satisfactory: CV
= 6.3% at a mean value (x) of 30.9 IU/1 (N = 6) and
CV = 8.5% at a x of 41 500 U'l (N = 6).
Detection limit
The threshold for detection of human chorionic
gonadotropin was calculated as the human chorionic
gonadotropin value corresponding to the mean plus
3 x SD of the zero light intensity (14). The highest
light intensities of the zero standard concentration
showed x = 0.06%, standard deviation (SD) = 0.03
(N = 5); the detection threshold was 0.15% of the
highest light intensity, equivalent to 1.25 IU/1 human
chorionic gonadotropin. To document the assay im-
precision in the low analytical range (15), repeated
measurements of 7 specimens of the I. R. P., prepared
by diluting the 75/537 reference preparation with high
sample diluent purchased from Amersham (modified
TRIS buffer, 50 mmol/1), were performed with the
human chorionic gonadotropin-60 assay. The theo-
retical values for these specimens were 10.0; 7.5; 5.0;
2.5; 1.25; 1.00 and 0.625 IU/1. Each sample was as-
sayed in duplicate in 7 separate runs on different days.
Table 2 summarizes the various values for the assay
variability. The standard deviations in the low con-
centration range were nearly constant. Even at the
calculated detection limit (1.25 IU/1) the measured
Tab. 2. Assay variabilities of the chemiluminescence assay de-
termined by repeated measurements of diluted 1st
I. R. P. in relation to the detection threshold
Human
chorionic
gonadotropin
(IU/1)
calculated
(diluted
I.R.P.)
10.0 7.5 5.0 2.5 1.25 1.0 0.625
Human
chorionic
gonadotropin
(IU/1)
measured
(N = 6/7)
10.3
9.9
10.4
10.2
9.8
9.9
—
6.3
6.7
7.4
7.5
7.1
7.1
—
5.1
3.8
4.3
5.1
4.5
4.5
—
2.1
1.7
2.3
2.1
2.5
1.6
2.5
0.8
0.8
1.6
1.2
1.3
0.8
1.2
0.5
0.8
1.1
1.0
0.9
0.5
1.1
0.3
0.0
0.6
0.6
0.5
0.4
0.7
x (IU/1)
SD
10.08 7.00
0.25 0.45
4.55 2.11
0.50 0.36
1.10
0.31
0.84
0.26
0.44
0.24
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Fig. 1. Determination of assay variabilities and recoveries of
the chemiluminescence assay at the low end detection
limit by measuring diluted 1st I. R. R
Mean values ± SD
concentration of the corresponding I.R.P. dilution
(1.25 IU/1) varied between 0.8 and 1.4 IU/1, which
did not overlap the next higher I.R.P. dilution (2.5
IU/1). This can be seen from the figure 1.
Linearity of dilutions
Since the human chorionic gonadotropin concentra-
tions have a wide range, up to more than 100 000 IU/1
in the serum of pregnant women, special attention
must be paid to the linearity of serum dilutions.
To test this, two sera with 800 and 1100 IU/1 human
chorionic gonadotropin were diluted successively with
diluent and the measured light intensities were plotted
versus the resulting human chorionic gonadotropin
values. In figure 2 the results of one serum dilution
1.00 Ί
ο
'S§
ο 0.10
10 100
Human chorionic gonadotropin [IU/1]
1000
Fig. 2. Linearity of the chemiluminescence assay checked by
serial dilution of serum with 800 IU/1 human chorionic
gonadotropin
ο —ο serum dilution
ο—ο standard curve
(serum with 800 IU/1 human chorionic gonadotropin)
are shown in relation to the standard curve. One can
see that the linearity of dilutions is good up to the
detection limit of the chemiluminescence assay.
Recovery studies
Two serum specimens were spiked with the 1st I. R. P.
human chorionic gonadotropin standard (dissolved in
high sample diluent) at three levels. The mean recov-
ery of 86% for the enhanced luminescence assay is
comparable with the recoveries (x = 90%) found in
serum Β for the enzyme immunoassay. Results are
given in table 3.
Tab. 3. Recovery study for the chemiluminescence and the en-
zyme immunoassay
Initial
human
chorionic
gonadotropin
concentration
(IU/1)
Human
chorionic
gonadotropin
concentration
expected (IU/1)
(I.R.P.
standard)
added)
Human
chorionic
gonadotropin
concentration
observed
assay (IU/1)
Human
chorionic
gonado-
tropin
recovery
(%)
Chemiluminescence assay
Serum A 25.3 22.3
(14.5) 123.1 98.3
340.0 291.1
88
80
85
Serum B
(20.8)
25.1
113.4
108.9
22.6
94.6
290.8
90
83
94
Enzyme immunoassay
Serum B
(15.00)
19.8
119.6
340.6
20.2
102.5
279.8
102
86
82
Carry-over
An important point during the human chorionic go-
nadotropin measurement in a routine laboratory is
the possible carry-over from a high value sample to
the next sample, which may be of lower concentration.
In contrast to the ES-22 system, which has a carry-
over rate of about 0.9% (16), the Amerlite® system
showed generally no carry-over, which was proved by
placing diluent round sera with high human chorionic
gonadotropin contents (> 50000 IU/1) in the niicro-
titre plate. We looked especially at the washing pro-
cedure performed with the wash station; in the sur-
rounding wells, containing only diluent, human cho-
rionic gonadotropin was not detectable, either hori-
zontally or vertically. The TECAN sample processor,
however, was a potential source of .such carry-over in
connection with the chemiluminescence human cho-
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rionic gonadotropin measurement. But this problem
could be minimized by special software adaptations
of the liquid handling procedure (see under "Connec-
tion of the Chemiluminescence assay ...").
Specificity
With the hypophyseal gonadotropins lutropin, folli-
tropin and with thyrotropin in high serum concentra-
tions, no appreciable cross-reactivities could be found
in the Chemiluminescence assay. Only one serum with
high lutropin content showed a slightly raised human
chorionic gonadotropin value with 2.3 IU/1. These
low rates of cross-reactivities are comparable with
those obtained with the enzyme immunoassay. Results
of the investigations of 5 sera are given in table 4.
Tab. 4. Cross-reactivity of sera with high gonadotropin con-
tents in the two compared immunoassays and cross-
reactivity of sera with endogeneous monoclonal anti-
bodies in the Chemiluminescence assay
Analyte Analyte
concentra-
tion
Human chorionic
gonadotropin
concentration
determinated with
chemilumi- enzyme
nescence immuno-
assay assay
Lutropin (serum 1)
Lutropin (serum 2)
Lutropin (serum 3)
Follitropin (serum 2)
Follitropin (serum 3)
Thyrotropin (serum 4)
Thyrotropin (serum 5)
IgA-myeloma (serum 6)
IgG-myeloma (serum 7)
IgG-myelöma (serum 8)
IgG-myeloma (serum 9)
105 IU/1
116 IU/1
44 IU/1
83.5 IU/1
67.4 IU/1
>80 mIU/1
62 mIU/1
15.5 g/1
10.5 g/1
18.7 g/1
42.8 g/1
2.3 IU/1
1.0 IU/1
1.2 IU/1
1.0 IU/1
1.2 IU/1
1.7 IU/1
0.3 IU/1
1.59 IU/1
< 1.25 IU/1
1.38 IU/1
8.4 IU/1
_i
—
1.7 IU/1
—
1.7 IU/1
—0.8 IU/1
—
—
— *
—
comparable with those obtained with the routine as-
say. Lipaemic sera of pregnant and non-pregnant
women all gave plausible positive or correct negative
results with both immunoassays (data not shown).
We did not investigate other effects like the high-dose-
hook effect or the prozone effect (19), because they
are irrelevant for gynaecological questions.
Method comparison
Method comparison of the Chemiluminescence and the
enzyme immunoassay
Sera (N = 152) were measured in both assays. Besides
the kit-controls, we used 3 external control sera and
1 pool serum in each run. Statistical evaluation was
made according to the linear regression procedure
given by Passing & Bablok (20).
In the measuring range beyond 10000 IU/1, deter-
minations of human chorionic gonadotropin in two
different assays are hardly comparable because of
dilutions of a different kind. We decided therefore to
split the statistical evaluation (fig. 3 a — c). In the range
up to 1000 IU/1 the two compared immunoassays
show high coefficients of correlation.
Method comparison of the Chemiluminescence assays
human chorionic gonadotropin-60 and human chorionic
gonadotropin-15
In the same way we compared the short version of
the Chemiluminescence assay for human chorionic
gonadotropin (incubation time 15 min) with the 60
min version (figures 4 a, b). Since the incubation pe-
riod was so short, only a maximum of 4 strips of
antibody coated wells instead of 8 were performed
because of the time delay caused by pipetting steps.
The coefficients of correlation show good agreement.
No remarkable non-specific interferences of human
chorionic gonadotropin determinations were found
by measuring sera of patients with monoclonal gam-
mopathies with high titres of certain immunoglobu-
liris. Only one of these sera caused a minor false-
positive human chorionic gonadotropin result in the
Chemiluminescence assay, which is noted also in table
4 (serum 9). This outcome does not prove, of course,
the ruggedness of the Chemiluminescence assay
against possible interferences with other heterophilic
antibodies (17, 18).
Artificially haemolysed sera of several pregnant and
non-pregnant women all gave correct results with the
Chemiluminescence assay (data not shown) and are
Over-all assay handling
The practicability of the Chemiluminescence kit was
comparable with the enzyme immunoassay with re-
spect to the special requirements of a routine labo-
ratory: simple handling and convenience, application
of ready-to-use reagents, informative computer pro-
tocol of results including raw data and perfected in-
strumentation units. Regarding the flexibility of the
assay, the Amerlite® system has several advantages.
The total assay-time is slightly shorter in the Chemi-
luminescence system (about 135 minutes for 30 human
chorionic gonadotropin determinations), but the
hands-on-times are comparable in both assays. The
flexibility of the new assay system can further be
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Fig. 3. Method comparison of the chemiluminescence and the
enzyme immunoassay
a) Measuring range: 0-70000 IU/1,
number of paired values: 152,
y = 0.773 χ + 111.5
coefficient of correlation: 0.995
b) Measuring range: 0-150 IU/1,
number of paired values: 68,
y = 1.019 χ + 0.516
coefficient of correlation: 0.976
c) Measuring range: 50-1000 IU/1,
number of paired values: 44,
y = 0.921 χ - 0.811
coefficient of correlation: 0.990
raised by implementing the TECAN robotic sample
processor, optional with on-line integration in the
laboratory computer system enabling computer as-
sisted down-loading of requested tests and with direct
sample identification by a barcode reader.
Connection of the chemiluminescence assay system with
the TECAN robotic sample processor
To accelerate and facilitate sample handling we con-
nected the new assay system with the robotic sample
processor TECAN RSP 5402. This is a dual-arm
sample processor for automatic liquid pipetting of
immunoassays. The two arms may be used in con-
junction or independently to carry out programmed
operations. Our aim was to create a pipetting program
permitting both high performance sample distribution
and minimization of serum contaminations.
Several precautions against carry-over were imple-
mented for the TECAN processor by the manufac-
turer: teflonized tips, built-in liquid level detectors to
prevent over-immersion of tips and special wash sta-
tions for rinsing tips inside and out between opera-
tions.
Nevertheless we saw carry-over rates of about 0.01 —
0.05% in pilot studies, according to a formula for the
carry-over rate given by Singer et al. (14). The possible
juxtaposition of unknown samples with highly differ-
ent human chorionic gonadotropin contents made
such carry-over rates unacceptable.for us. Therefore
the control software was Optimized for the special
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 11
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Fig. 4. Method comparison of the human chorionic gonadotropin-60 and human chorionic gonadotropin-15 versions of the
Chemiluminescence assay
a) Measuring range: 9 — 70000 IU/1, number of paired values: 62,
y = 0.941 χ - 45.1
coefficient of correlation: 0.994
b) Measuring range: 0—100 IU/1, number of paired values: 28,
y = 0.969 χ + 1.549
coefficient of correlation: 0.989
Secondary
rack
Primary
rack
Microtitre Human Standards 1-6
plates 1-3 chorionic Controls 0,702/03
gonadotropin Pool serum
samples Conjugate
1-X
Fig, 5. Layout of the distribution of human chorionic gonadotropin samples with the TECAN sample processor
requirements of fast distribution combined with min-
imized contamination: after each duplicate sample
distribution tips first drive to a waste position, where
serum residues are ejected with 800 μΐ of distilled
water. Only then, the arms are directed to the inner
wash station, where tips are washed around with
another 2000 μΐ water. Carry-over is thereby reduced
to less than 0.005%. This procedure is time-consum-
ing. For this reason, it is only programmed for the
distribution of samples, not for the distribution of
standards or conjugate. In addition the time delay of
this mode of operation is compensated through the
choice of a simultaneous two-arm configuration of
the robotic sample processor. The two single arms
work together simultaneously, first for multi-pipetting
conjugate to the microtitre plates, and then for pi-
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petting sera. For duplicates both arms distribute one
sample temporarily interlocked from the primary tube
to the two secondary tubes. In figure 5 the layout for
the sample processing is illustrated. The pipetting of
30 sera including standards, 3 control sera, 1 pool
serum arranged in replicates after 10 samples respec-
tively and multi-pipetting of conjugate into each well
requires a total of 21 minutes.
Discussion
The aim of this study was to determine whether a
new two-site immunoassay system produces compa-
rable or better performance data than our routine
enzyme immunoassay. We stipulated several special
requirements for the novel assay: good precision and
reliability data, no susceptibility to interferences, good
correlation with the former assay, short assay time,
easy handling and flexibility, possible automation and
effortless integration in the laboratory.
Evaluating 152 pregnancy sera, we found that the
enhanced chemiluminescence assay for human cho-
rionic gonadotropin has a good practicability with
respect to the above mentioned criteria: the within-
series and between-series precisions are good with
variation coefficients of 3 and 5% on average. The
assay has a wide working range; the lower detection
limit and the linearity are excellent. Recovery was
satisfactory at 86% on average. The cross-reactivity
measurements point to the excellent specificities of
the employed antibodies. Remarkable interferences
through immunoglobulins in patients with mono-
clonal gammopathies could not be detected. Possible
interferences through heterophilic antibodies, recently
reviewed by Boscato & Stuart (18), did not appear
during our investigation.
The printout of results is satisfactory with respect to
clarity, presentation of data and raw data from the
microtitre plate. Also enclosed with the program is a
quality control memory for three eligible control sera.
In general the chemiluminescence assay system per-
mits a very effective handling, and the reagents have
a long shelf life.
The method comparison with the enzyme immunoas-
say demonstrates the comparability of results. The
coefficients of correlation (r) vary between 0.976 and
0.995. In the upper range, however, the chemilumi-
nescence assay shows slightly lower chorionic gonado-
tropin values, but in the important diagnostic range
between 50 and 1000 IU/1 the correlation coefficient
(r = 0.990) is satisfactory. Since ectopic pregnancies
are often a cause of acute gynaecologic emergency
situations, flexibility is of pivotal importance in the
judgement of a human chorionic gonadotropin assay
used in a clinical chemistry laboratory. From this
piont of view the chemiluminescence assay system
offers a remarkable advantage compared with the
modular batch ELISA system. Because of its short
incubation time and the possibility of adaptable
length of the microtitre strips together with a very
short measuring tiine (within 2 minutes) the assay
format gains high flexibility. Additionally the corre-
lation of the 15 min version to the normal 60 min
version of the chemiluminescence assay is remarkable.
Another advantage is the total absence of carry-over
within assay runs pursuant to the configuration of
the assay format.
The absence of automation, an undeniable disadvan-
tage of the Amerlite® compared with the ES-22 sys-
tem, can be compensated by use of an automatic
sample processor. We applied the dual-arm processor
TECAN RSP 5402. With specially adapted software
programs we optimized sample handling, resulting in
an adequate distribution rate combined with mini-
mized carry-over (below 0.005%). In this way the
total assay times are shorter with this system com-
pared with the modular batch analyser system for the
performance of the enzyme immunoassay.
Conclusion
The new chemiluminescence assay for human cho-
rionic gonadotropin in connection with the TECAN
RSP 5402 processor is an advanced and versatile
system for the determination of human chorionic go^
nadotropin in laboratories with high daily sample
numbers. The assay is rapid, simple to handle and
without detected susceptibility to interferences. Total
assay times with the Amerlite® and the ES-22 system
are comparable, but the Amerlite® human chorionic
gonadotropin assay can also be performed in a short
version. In addition the enhanced chemiluminescence
assay system offers the advantages of a flexible multi-
batch analyser; the possibility of parallel test perform-
ances within gynaecological analytes like lütropin,
follitropin or prolactin indicates the suitability of the
system in the gynaecological unit of a clinical chem-
istry department.
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